摘要
[目的]研究芪参清肝汤联合拉米夫定治疗慢性乙型肝炎(Chronic hepatitis B,CHB)HBeAg阳性的疗效。[方法]59例CHB患者随机分为2组,治疗组30例以芪参清肝汤联合拉米夫定治疗,对照组29例以拉米夫定治疗,疗程52周,观察2组治疗前后血清乙肝病毒(HBV)载量、乙肝标志物、肝功能的变化。[结果]经过52周的治疗,治疗组中93.33%的患者HBV转阴,对照组为72.41%,差异有统计学意义(P<0.05)。2组患者HBeAg阴转率分别为46.67%、20.69%,差异有统计学意义(P<0.05);HBeAg血清学转换率分别为33.33%、17.24%,差异无统计学意义(P=0.16)。2组患者丙氨酸氨基转移酶复常率分别为96.66%和79.31%,差异有统计学意义(P<0.05)。[结论]芪参清肝汤联合拉米夫定治疗CHB HBeAg阳性能提高抗病毒应答,其疗效优于单纯拉米夫定治疗。
[Objective]To study clinical efficacy of Qishen Qinggan Decoction combined with Lamivadine for the treatment of chronic hepatitis B（CHB）of HBeAg positive.[Methods]Fiftynine CHB patients were randomly divided into two groups,30 in treatment group,29 in control group.The treatment group were given Qishen Qinggan Decoction combined with Lamivadine,and the control were treaeted by Lamivadine.Serum levels of HBV-DNA,HBV-Mark and liver function were detemined after 52 weeks of treatment.[Results]The serum HBV-DNA was undetectable in 93.33% patients of treatment group versus（vs）72.41% of control group（P0.05）.The rate of serum HBeAg became negative in 46.67% patients of treatment group vs 20.69% of control（P0.05）.The rates of serum HBeAg seroconversion of 2 groups were 33.33% vs 17.24%（P=0.16）.The normalization of ALT of 2 groups was 96.66% vs 79.31%（P0.05）.[Conclusion]Qishen Qinggan Decoction combined with Lamivadine can improve antiviral response for the treatment of CHB of HBeAg positive.
出处
《中国中西医结合消化杂志》
CAS
2011年第3期155-157,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
基金
江苏省中医药局资助项目(LZ09029)
关键词
芪参清肝汤
乙型肝炎
慢性
拉米夫定
Qishen Qinggan Decoction
chronic hepatitis B
Lamivadine
